Earnings Releases·Nov 3, 2026, 8:10 AM ET

AdaptHealth Corp. — Third Quarter 2026 Earnings Summary

Net revenue reached $745.6 million (up 10.9% YoY) with 12.8% organic growth, though net loss widened to $168.2 million due to a $184.8 million goodwill write-down; Adjusted EBITDA declined 2.9% YoY to $141.9 million.
Fiscal 2026 guidance was revised upward for net revenue ($2.88–$2.90 billion) and Adjusted EBITDA ($510–$525 million), while free cash flow guidance was lowered to $50–$75 million.
The company cleared regulatory hurdles for the $235.0 million sale of its Diabetes Health business, expected to close in early 2027, and reported strong growth in registered myAPP users (+88% to 615,000).
Year-to-date free cash flow dropped significantly to $2.6 million from $140.1 million, while long-term debt increased to $1.87 billion as the company navigates its transformation period.